Clinical Trial Update: A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing tivozanib hydrochloride to sorafenib in refractory advanced renal cell carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)
• tivozanib hydrochloride (tivozanib)

Snippet

Sponsor: AVEO Pharmaceuticals, Inc. | Conditions: Carcinoma, Renal Cell | Phase 3 | Status: COMPLETED | Results posted: 2020-02-20